Winter Innovations

What they build

EasyWhip is a disposable two-part suture needle. The two halves pass through tissue together, separate to go around each side of a graft, then reconnect, so a surgeon can whipstitch a tendon graft fixed on both ends in one pass. It also enables the company's WhipLock stitch, a whipstitch/Krackow hybrid. The pitch is speed and versatility: three stitch patterns from one $350 disposable, fewer needle passes, no extra components. A companion bench instrument, StitchStand, holds the graft during prep.

VERIFIED The clinical problem is real and the mechanism is genuinely novel: incumbents' single-part looped needles cannot do the separate-and-reconnect move without infringing the patents. CAVEAT All performance data is pre-clinical bench testing on porcine and cadaver tissue; the company's own product sheet states human clinical results are unknown.

Team

VERIFIED Two co-founders run the company: Lia Winter (CEO) and Preston Dishner (COO), both out of a University of Tennessee dual-master's program (2017–2019), with the company spun out of UT's Knoxville research park. Lia is the named inventor on the core patent, so she is a real technical founder, not a figurehead. The UT origin is well corroborated (UT Foundation on the cap table, ZeroTo510 accelerator, LaunchTN backing).

UNVERIFIED The specific degrees are company-stated only; LinkedIn was auth-blocked during diligence, so treat the resumes as claimed. The structural read is the concern, not the people: only two full-time employees (PitchBook “Current Team (2)”; ~4 FTE per the LaunchTN memo), every other function outsourced, no full-time commercial or sales leader, no CFO. Both are first-time founders with no prior medtech exit and neither has ever hired or managed a sales rep — which is precisely what the Series A is meant to fund. LaunchTN's own memo flags reliance on the founders and the need for experienced sales leadership as the primary execution risk. The board is investor-heavy (Angel Roundtable, Ballad Ventures) with no marquee medtech-operator independent.

Funding and cap table

VERIFIED Capital-efficient and clean. The company built a cleared, selling product on roughly $1.9M of dilutive cash (a 2019 services SAFE, two convertible-note bridges in 2020 and 2021, and a $1.0M priced seed in 2023 at an $8.5M post) plus about $2.1M of non-dilutive grants — the full NSF SBIR sequence (Phase I → Phase II → TECP, award numbers verifiable in the published papers) and LaunchTN matches. All convertibles converted to preferred on 2/21/2023, so there is no note or SAFE overhang going into the round. Founders still hold 51.7% fully diluted (Lia 38.75%, Preston 12.92%).

CLAIMED / OPEN The Series A is a $2M raise at a $10–12M post “dependent on lead” — the price is unset because no lead has committed. Only $500K is soft-circled, from LaunchTN, and that is contingent on a 1:1 match with a $1M minimum to close and a ~120-day clock that runs out around late May 2026. Cash is ~$708K (about 12.5 months). The register is fragmented: 40+ preferred holders, many $25K checks, assembled from two bridge rounds. Valuation growth has been modest ($8.5M post in 2023 to a $10–12M ask now).

Traction and revenue

VERIFIED This is the crux, and it is weak. Product revenue: $25K (2022), $90K (2023), $182K (2024), $192K (2025) — the 2022–2024 figures match the filed federal tax returns to the dollar, which is a genuine point of management integrity. But the most recent year grew only +5.5%, essentially flat, and lifetime sales are ~$489K on ~1,900 units. About 77% of 2025 “income” is SBIR grant money, not product; the business posts a net loss every year and has never been close to commercially self-sustaining.

UNVERIFIED Committed commercial demand is effectively zero. The AdventHealth “national contract” is a price-and-eligibility master that commits no volume and carries a no-penalty clause — and the data-room copy is a partial extract (5 of 23 pages) with a blank AdventHealth signature block and no execution date, so even “executed” is unproven. The Ascension, HCA, and USPI “relationships” are one-page vendor-credentialing sheets (a supplier number and a price list), not contracts. A claimed Tampa General contract is not in the room. The entire revenue base is ~16 named surgeons whose captured volume roughly equals total company revenue — high concentration, not a repeatable engine. Everything larger ($28M “system”, $19–34M geographic) is AcuityMD-modeled TAM, not pipeline.

CONTRADICTED The plan projects 50% / 192% / 350% revenue growth off that flat base, at $875K per salesperson — from a team that has never employed a sales rep. Founder-led selling peaked at $192K/yr. The “85% gross margin” claim is really ~62% including distribution; the deck rounds ~1,900 units to “2,000+” and $489K to “$500K+.”

Regulatory and IP

VERIFIED The regulatory and IP asset is the strongest part of the story, and it checks out against primary sources. EasyWhip's 510(k) (K210675, cleared 3 May 2021, Class II, product code GAT) is real — it returns in openFDA under applicant Winter Innovations, Inc. The patent moat is granted and company-owned: US 10,792,036, 11,213,290, and 11,439,386, all assigned to Winter Innovations (USPTO assignment history shows the clean inventor→LLC→Inc chain, no founder-retained split), running to ~2039, with the core apparatus additionally granted across ~14 foreign jurisdictions. The EASYWHIP word mark is live. Three peer-reviewed publications (two in ASMR, one in the top-tier AJSM) support the biomechanics.

CAVEAT The studies are all funded by Winter Innovations and share a financially-conflicted author, so they are sponsored, not independent. “Superiority” holds only versus a plain whipstitch and only in one tendon; head-to-head, EasyWhip is biomechanically equivalent to Arthrex FiberTag, and WhipLock is actually slower to place. The company is not itself ISO 13485 certified (only its contract manufacturers are). The “WhipLock” name — the marketed differentiator — is unregistered, the method and crimp patents are US-only, and two 2025 reinforcement-tag provisionals appear to have lapsed. The line-extension “Family” 510(k) is not yet cleared.

Market and competition

CLAIMED The company frames a ~$310–416M US orthopedic-suture entry market inside a $6.8B global soft-tissue-repair headline at 6–8% growth. VERIFIED The one independent market document in the room, SmartTRAK, sizes US soft-tissue fixation at $2.54B growing to $3.12B at a slower +5.2% CAGR — and every growth driver it names (all-suture anchors, knotless designs, biologics, robotics) is a category EasyWhip does not sell into. So the third-party number describes the implant market, not the suture-device niche; it undercuts the TAM more than it supports it.

WEAK MOAT The market is dominated by Arthrex (the acknowledged leader in needles and sutures), Smith+Nephew, Stryker, CONMED, DePuy, and Zimmer Biomet — PitchBook lists all of them as WI's closest comps. Arthrex already forward-cites WI's patents and matches EasyWhip on the bench. The comp base rate is discouraging: same-stage suture startups stall at seed (Atreon $5.4M, BRIJ $12.75M, Native $3M, all still seed per Harmonic), while the companies that scale are anchor/implant plays. A two-pass whipstitch reads as a graft-prep technique — a feature and a plausible small tuck-in, not a durable standalone platform. The exit comps the deck leans on ($85–250M) are all implant/biologic acquisitions, a different product class than a $350 consumable.

Second sweep — what changed

A deeper nine-agent pass (22 agents across both sweeps) surfaced material the data room does not lead with. It moved the rating from 5.5 to 5.0.

• Reimbursement is the real ceiling. VERIFIED EasyWhip is not separately paid — it is bundled into the procedure fee, an “additive device that does not displace incumbent systems” (the company's own memo). The $2,000/surgery value it sells accrues to the payor, not the hospital that buys it. That explains the flat revenue far better than a sales-headcount gap, and it caps the commercial engine structurally rather than for lack of reps.
• The cash is grant-propped. VERIFIED 2025 cash rose only because the company banked $196K of unearned deferred grant money; strip it and cash fell $136K. The standalone business burns ~$32K/month, ~42% of the $708K cash is encumbered deferred grant liability, and the plan books an unawarded $500K Phase IIB as 2027 income. The LaunchTN covenant deadline (late May 2026) has already passed with the match unmet.
• The ask prices as a down round at the floor. VERIFIED At a $10M post the Series A is $0.459/share, below the 2023 seed at $0.49. A $250–500K check buys 2–5%, and the charter defining the liquidation stack ahead of it is a 0-byte empty file in the room.
• New de-risking, in their favor. VERIFIED A second FDA clearance landed — the EasyWhip Family line extension (K261021, cleared July 2026, ~96-day review) is live, not pending — and the federal litigation and IP-opposition record is clean.
• Two diligence holes. UNVERIFIED The founders each drew ~$110K in 2024 (combined more than the company's product revenue), and there is no product-liability policy anywhere in the room for a load-bearing surgical device sold by a two-person company.

Bull case

• A genuinely de-risked asset: FDA 510(k) confirmed in openFDA, three granted company-owned patents to ~2039 (clean assignment chain, no founder split, no university drag), and a live trademark — exactly the IP profile a Series A investor wants.
• Capital-efficient and honest: built a cleared, selling product on ~$1.9M dilutive plus ~$2.1M non-dilutive NSF/LaunchTN money, and the reported revenue reconciles to the filed tax returns to the dollar.
• Real, if small, commercial proof: four years of paying customers, one large system (AdventHealth) granting system-wide vendor and pricing approval, 16 KOL surgeons, ~62% product gross margin with room to improve at volume.
• Fits the Daxos check exactly: a $2M round at a $10–12M post with no lead committed — a $250–500K check buys a meaningful stake and Daxos can help fill or shape the round, unlike the $10M+ raises that price a small fund out.
• Non-dilutive validation and a top-tier publication (AJSM) give more third-party signal than most Series A medtechs carry at this size.

Bear case

• Revenue is tiny and flat: ~$489K lifetime, $192K in 2025 at +5.5% — the commercial story is stalling, not compounding, and 77% of income is grants.
• Committed demand is ~$0: the AdventHealth “contract” commits no volume (and its room copy has a blank counterparty signature), the other three systems are credentialing sheets, and a claimed Tampa General contract is missing. ~16 surgeons are the whole company.
• The Series A thesis is unproven at its core: 50%/192%/350% projected growth and $875K/rep from two first-time founders who have never hired a sales rep, with 50% of the raise going to a salesforce that does not exist.
• Weak competitive durability: only biomechanically equivalent to Arthrex FiberTag, Arthrex already forward-cites the patents, the WhipLock method is US-only and the “WhipLock” name is unregistered. Same-stage suture peers stall at seed.
• Round risk: no lead, price unset, and the only commitment ($500K LaunchTN) is contingent on a 1:1 match with a deadline running out around late May 2026.

Key risks

• Commercial-scaling risk is the whole investment: the model works only if first-time founders can hire and run a productive direct salesforce — a capability with zero evidence behind it today.
• Incumbent absorption: Arthrex or a peer can treat the two-part technique as a feature and design around a US-only method claim ex-US, leaving EasyWhip a niche disposable rather than a platform.
• Key-person concentration on Lia Winter (sole core inventor, lead seller, CEO, fundraiser); losing her hits product, commercial, and financing at once.
• Grant cliff: SBIR has carried the company; the plan assumes grants taper to zero exactly as commercial revenue is supposed to take over, with no proof that handoff works.
• Governance housekeeping: fragmented 40+ holder cap table, an investor-heavy board, a partial/unsigned key contract in the room, and a PitchBook “co-founder” label on the largest investor that should be reconciled.

Questions for the founders

1. Show the fully-executed AdventHealth agreement and the actual purchase orders under it. What committed or booked revenue — not modeled TAM — exists beyond the ~16 named surgeons?
2. Revenue was flat in 2025 (+5.5%). What specifically changes to get to 50% growth in 2026, and what is the real evidence for $875K per rep when you have never employed one?
3. Head-to-head, EasyWhip is biomechanically equivalent to Arthrex FiberTag. What stops Arthrex — who already cites your patents — from matching the technique, and where is your durable edge ex-US given the method patent is US-only?
4. Who leads commercial? Name the sales hire and the plan, since 50% of the raise funds a function neither founder has built.
5. Who is the lead, and what is the real price? A $10–12M post “dependent on lead” on ~$192K of flat revenue needs justifying against your own comps.
6. Did the 2019 SAFE’s reinforcement-tag provisionals convert, or did they lapse in Feb 2026? Confirm the current status of the WhipLock and StitchStand marks.